Dr. Woldu is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
5323 Harry Hines Boulevard
Dallas, TX 75390Phone+1 214-645-8765Fax+1 214-645-8769
Summary
- Dr. Solomon Woldu is an urologist in Dallas, TX and is affiliated with multiple hospitals in the area, including William P. Clements, Jr. University Hospital, Parkland Health & Hospital System, JPS Health Network, and Veterans Affairs North Texas Health Care System. He received his medical degree from Columbia University College of Physicians & Surgeons and has been in practice 7 years. He specializes in surgical oncology and is experienced in urology and urologic neoplasms.
Education & Training
University of Texas Southwestern Medical CenterFellowship, Minimally Invasive Urologic Surgery, 2016 - 2018
New York Presbyterian Hospital (Columbia Campus)Residency, Urology, 2011 - 2016- New York Presbyterian HospitalInternship, Transitional Year, 2010 - 2011
Columbia University Vagelos College of Physicians and SurgeonsClass of 2010
Washington University in St. LouisB.A., Biology, 2002 - 2006
Certifications & Licensure
TX State Medical License 2016 - 2025- American Board of Urology Urology
Clinical Trials
- Checkpoint Inhibitor and Radiation Therapy in Bulky, Node-Positive Bladder Cancer Start of enrollment: 2021 Sep 06
- Gemcitabine Versus Water Irrigation in Upper Tract Urothelial Carcinoma Start of enrollment: 2021 Nov 29
Publications & Presentations
PubMed
- 5 citationsFeasibility and Safety of Robotic Excision of Ipsilateral Retroperitoneal Recurrence After Nephrectomy for Renal Cell CarcinomaRashed Ghandour, Andre Miranda, Nirmish Singla, Xiaosong Meng, Dmitry Enikeev
Urology. 2020-08-21 - 1 citationsStandardization of the evaluation and surveillance of patients with BCG unresponsive high grade non-muscle invasive bladder cancer clinical trials.Yair Lotan, Piyush Agarwal, Peter Black, Rian Dickstein, Ashish M Kamat
Urologic Oncology. 2024-08-01 - 41 citationsPathologic response and surgical outcomes in patients undergoing nephrectomy following receipt of immune checkpoint inhibitors for renal cell carcinoma.Nirmish Singla, Roy Elias, Rashed Ghandour, Yuval Freifeld, Isaac Bowman
Urologic Oncology. 2019-09-12
Authored Content
- Multi-Institutional Evaluation of the Prognostic Significance of EZH2 Expression in High-Grade Upper Tract Urothelial CarcinomaMay 2018
- Multi-Institutional Evaluation of the Prognostic Significance of EZH2 Expression in High-Grade Upper Tract Urothelial CarcinomaMay 2018
- Multi-Institutional Evaluation of the Prognostic Significance of EZH2 Expression in High-Grade Upper Tract Urothelial CarcinomaMay 2018
Press Mentions
Socioeconomic Factors Linked to Immunotherapy Use in Urologic CancersSeptember 10th, 2024- Socioeconomic Disparities Impact Immunotherapy Use in Urologic CancersSeptember 9th, 2024
- Widespread Disparities Exist in Treating Advanced CancersSeptember 4th, 2024
- Join now to see all
Grant Support
- T32 GrantNational Institute of Health2016–2018
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
